To assess complication rates and intermediate oncological outcomes of laparoscopic-assisted cryoablation (LCA) in patients with small renal masses (SRMs). 
Introduction
In 2012 there were an estimated 338 000 new cases of kidney cancer in the world, being the ninth most common cancer in men and 14th most common in women [1] . In Europe, the incidence was estimated to be 115 200 cases with 49 000 mortalities in 2012 [2] . The liberal use of advanced imaging techniques for unrelated conditions has significantly contributed to an early detection of renal masses, most of which are cancers and <4 cm when being diagnosed [3, 4] . Both European and American treatment guidelines for small renal masses (SRMs) recommend preserving renal function, whilst maintaining oncological control, with partial nephrectomy (PN) as the recommended modality [5, 6] . For the past decade, ablative techniques have proven effective in selected patients where the modality can offer a minimally invasive approach with the potential benefits of low complication rates, decreased morbidity, and acceptable intermediate oncological outcomes [7] [8] [9] . In a survey of 64 American academic institutions performing ablative treatment of SRMs, Patel et al. [10] found laparoscopic-assisted cryoablation (LCA) to be the most frequently applied ablative procedure. Yet, current guidelines from the European Association of Urology withhold from making recommendations regarding cryoablation due to a lack of high-quality data. Much of the currently available data is based on single centre experiences with relative low patient numbers and limited follow-up.
The present study was initiated by the European Registry for Renal Cryoablation (EuRECA) with the aim of investigating oncological outcomes and complication rates in patients treated with LCA between 2005 and 2015 in a large multiinstitutional cohort.
Patients and Methods
Included were patients treated with LCA for a T1a, nonmetastatic, unilateral SMR between 2005 and 2015 in one of eight European centres. All patients had consented to LCA and each centre selected patients and performed the diagnostic evaluation according to their own entry criteria. Commercially available cryosystems and cryoprobes (Galil Medical, Arden Hills, MN, USA) were used at all centres. All tumours were treated in a single session, which generally consisted of two freeze cycles (2 9 10 min) reaching at least À40°C in the tumour. The tumour was passively thawed to 0°C between the two freeze cycles.
Aims
The primary aim of the present study was to investigate oncological outcomes after LCA. Treatment success was evaluated by postoperative follow-up imaging, typically adhering to a protocol of 3, 6 and 12 months imaging, and thereafter on a yearly basis. Follow-up imaging comprised either CT or MRI. 'Residual unablated tumour' was defined as residual tumour at the ablation zone found within the first 6 months from diagnosis, and where no contrast-enhanced scan had previously documented adequate ablation. 'Local tumour progression' was defined as the appearance of tumour foci at the ablation zone and occurring after documented adequate ablation from at least one contrast-enhanced scan. Disease-free survival (DFS) was defined as the time from cryoablative treatment until either residual unablated tumour, local tumour progression, or metastatic disease was diagnosed. Overall survival (OS) was defined as the time from cryoablative treatment until patients died of any cause during follow-up. Definitions were adapted from the working group on Image-Guided Tumour Ablation Standardization of Terminology and Reporting Criteria which has been endorsed by the AUA Clinical T1 Renal Mass Guideline Panel [6, 11] .
The secondary aim of the study was to investigate the occurrence of postoperative complications within 30 days of LCA. Postoperative complications were defined according to the Clavien-Dindo classification system [12] . Any complication having a grade ≥IIIa was defined as a severe complication.
Data Management and Statistical Analysis
After approval from each of the eight participating centres scientific and/or ethical committees, treatment and follow-up data were collected from prospectively maintained local databases and combined for retrospective analysis. Covariates included age, gender, body mass index (BMI), American Society of Anesthesiologists (ASA) score, history of previous RCC, tumour size, tumour side, biopsy outcome, laparoscopic approach, postoperative complications, postoperative hospital stay, and follow-up details.
Statistical analyses and reporting, as well as interpretation of the results, were performed according to recommended guidelines [13, 14] . Medians and interquartile ranges (IQRs) or proportions were reported for continuous or categorical variables, respectively. Variables predicting overall and severe complications were evaluated using multivariable logistic regression models and summarised with odds ratios (ORs) and 95% CIs. Disease-free survival (DFS) and overall survival (OS) were estimated using the Kaplan-Meier method. Factors predicting DFS and OS were evaluated using multivariable Cox regression models. There were a very limited number of cancer-related deaths, thus we refrained from cancer-specific survival analyses. BMI was not included in the regression models due to the extent of missing data. Statistical significance was evaluated based on a two-sided significance level of 0.05. Data analyses were conducted using STATA v.14 software (StataCorp, LP, USA).
Results

Baseline Characteristics
In all, 808 patients were treated with LCA at eight European centres during the 10-year study period. Table 1 presents patient demographics, tumour characteristics, and treatment details. The median (IQR) age was 67 (58-74) years and 69% of the patients were males. The median (IQR) BMI was 26 (23.9-28.9) kg/m 2 and the median (IQR) ASA score was 2 (2-3). Tumour distribution between the right and left kidney was 54.6% vs 45.4%, respectively. A solitary kidney was present in 95 patients (11.8%) and 88 patients (10.9%) had a history of previous RCC. The median (IQR) tumour size in cross-sectional imaging was 25 (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) mm and 589 patients (72.9%) had a biopsy confirmed RCC. A transperitoneal laparoscopic approach was used in 77.7% of the patients and a retroperitoneal approach was used in 22.3% of the patients. The median postoperative hospital stay was 2 days. The median follow-up for the entire cohort and for patients with a confirmed RCC was 34 and 36 months, respectively.
Complications
Analyses for complications as an outcome were performed on the entire cohort of 808 patients, among which, 134 complications (16.6%) were reported. These included 47 Clavien-Dindo grade I, 61 grade II, 10 grade IIIa, nine grade IIIb, three grade IVa, one grade IVb, and three grade V complications. There were severe complications (grade ≥IIIa) in 26 patients (3.2%). The Clavien-Dindo classification and clinical details are presented in Table 2 . Multivariate logistic regression analyses showed that an ASA score of 3 was associated with a nearly three-fold increased risk of overall complications (OR 2.85, 95% CI 1.32-6.20; P = 0.005).
Conversely, a transperitoneal laparoscopic approach was associated with a decreased risk of overall complications (OR 0.59, 95% CI 0.38-0.91; P = 0.02). None of the analysed risk factors were found to be significantly associated with severe complications (Table 3 ).
Oncological Outcomes
After excluding patients with benign or inconclusive histology (219), patients with a history of previously diagnosed RCC (70) and patients who developed a metachronous tumour (five), the final sub-cohort for oncological outcome analysis consisted of 514 patients. Some variables have missing data and are marked with the actual number of patients. (Fig. 2) . A total of five patients (1.0%) died due to kidney cancer-specific causes after a medium (IQR) follow-up of 36.4 (11.6-36.7) months. Apart from age being a significant predictor of OS (hazard ratio 1.05, 95% CI 1.02-1.09; P = 0.001), ASA score, tumour size, tumour side, single kidney, and surgical approach were not significant predictors of DFS or OS (multivariable data not shown).
Discussion
Establishing the ideal treatment for SRMs remains a clinical challenge. The present study has shown that cryoablation is a potential treatment alternative for patients with T1a renal tumours unfit for extirpative surgery. Ideally, ablative treatment should be compared with PN in a randomised and prospective setting. However, in the absence of such data, retrospective results, such as those presented here, are the best available evidence at the moment. Therefore, the objective of the present non-comparative study was to investigate oncological outcomes and postoperative complications associated with LCA in a large, retrospective and multi-institutional cohort from eight European centres.
Various case studies (institutional series) on cryoablation have been published, often with a limited number of patients and a combination of laparoscopic and percutaneous [9, 15] . A few population-based studies have investigated which patients might benefit most from ablative treatment and which modality might offer the best outcomes [16] [17] [18] . Such studies offer valuable information, but are significantly limited by the shortage of detailed information about the treatment of complications and the established grading systems have not been applied. In the present study, 808 patients were eligible for analyses on the occurrence of complications, and there was an overall complication rate of 16.6%. Severe complications (Clavien-Dindo grade ≥IIIa) occurred in 3.2% of the patients, of which, three patients had a grade V complication and died within 30 days of the procedure. Previously published studies, including two meta-analysis, have reported overall and severe complication rates ranging between 10% and 20% and between 1% and 10%, respectively [9, [19] [20] [21] [22] . The present study showed that an ASA score of 3 was significantly associated with an increased risk of overall complications (OR 2.85); however, the ASA score was not a predictor of severe complications. In two previous studies, the ASA score was not found to be a significant predictor of complications; however, nephrometry scores were found to be significantly associated with complications after LCA [19, 23] . These results are in contrast to the findings by Lagerveld et al. [24] where the PADUA (Preoperative Aspects and Dimensions Used for an Anatomical classification) and R.E.N.A.L. (Radius; Exophytic/Endophytic; Nearness; Anterior/Posterior; Location) nephrometry indices both failed to predict postoperative complications after LCA. Further studies focusing on postoperative complications are needed in an attempt to improve patient selection criteria for ablative treatment.
In the present study, there were 32 cases (6.2%) of treatment failure, which was lower than what was reported by Klatte et al. [22] in a recently publish meta-analysis comparing LCA with laparoscopic PN (9.4%). Many studies have reported short-and intermediate-term oncological outcomes, but only a few studies have reported long-term data after LCA. Caputo et al. [7] reported a recurrence-free survival rate of 86.5% after 5 and 10 years. Johnson et al. [9] reported a progression-free survival of 95% and 91% after 5 and 10 years, respectively. Zargar et al. [15] reported the largest study to date, with 153 biopsy-verified RCC tumours, a 5-year recurrence-free survival rate of 79%, and 56 patients still at risk 60 months after treatment. In the present study, 514 patients were eligible for survival analysis and the 5-and 10-year DFS was found to be 90.4% and 80.0%, respectively. The uncertainty of the estimates increases significantly when the follow-up time surpasses 5 years due to the limitation of available data. Furthermore, it is noteworthy that some treatment failures (local progression and metastatic events) were found to occur at >5 years of follow-up in this study, suggesting that a prolonged follow-up period might be indicated.
None of the covariates in the multivariate analysis, including tumour size, were found to be associated with DFS. Furthermore, only a limited number of studies have investigated the influence of tumour size on oncological outcomes, and conflicting results have been reported [24, 25] . It is likely that tumour size is an inadequate measure of tumour complexity relative to cryoablation's ability to achieve disease control. As demonstrated by Sisul et al. [26] , Camacho et al. [27] , and Nielsen et al. [28] , nephrometry indices such as the PADUA and R.E.N.A.L. scores might prove to be better predictors of cryoablation outcome than tumour size alone, but this needs further exploration as nephrometry data were not available for the present study.
The present study has some notable limitations. Firstly, the results require interpretation in the light of their nonrandomised nature and thus, selection bias and residual confounding are inevitable. Secondly, missing data on several parameters (comorbidity score, nephrometry score, tumour grading, intraoperative complications etc.) were a major limitation. The retrospective and multi-institutional nature of the data determined the availability of covariates that could be included in the predictive models. Also, a substantial percentage of the biopsies had unknown histology and were excluded from the survival analysis, thus potentially prompting bias. We also lacked confirmatory data on treatment failures. Information was not available to investigate the distribution of imaging vs histological confirmation. Traditionally, contrast enhancement on cross-sectional imaging has served as a predictor for treatment failure owing to a strong correlation, but contrast enhancement has also been shown to resolve spontaneously, thus not always representing treatment failure [29, 30] . Finally, owing to the slow growing nature of SRMs, a longer follow-up period would have allowed for additional accruement of failure cases.
Conclusions
This large multi-institutional study of LCA provides evidence of satisfactory intermediate-term oncological outcomes for SRMs. However, although LCA is considered a minimal invasive procedure, risk of complications should be considered when counselling patients. Finally, an ASA score of 3 was associated with an increased risk of postoperative complications, whereas a transperitoneal approach was associated with a decreased risk of postoperative complications.
